<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Zonisamide add‐on therapy for focal epilepsy - Brigo, F - 2020 | Cochrane Library</title> <meta content="Zonisamide add‐on therapy for focal epilepsy - Brigo, F - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001416.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Zonisamide add‐on therapy for focal epilepsy - Brigo, F - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001416.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001416.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Zonisamide add‐on therapy for focal epilepsy" name="citation_title"/> <meta content="Francesco Brigo" name="citation_author"/> <meta content="Franz Tappeiner Hospital" name="citation_author_institution"/> <meta content="dr.francescobrigo@gmail.com" name="citation_author_email"/> <meta content="Simona Lattanzi" name="citation_author"/> <meta content="Marche Polytechnic University" name="citation_author_institution"/> <meta content="Stanley C Igwe" name="citation_author"/> <meta content="Federal Teaching Hospital" name="citation_author_institution"/> <meta content="Masoud Behzadifar" name="citation_author"/> <meta content="Lorestan University of Medical Sciences" name="citation_author_institution"/> <meta content="Nicola Luigi Bragazzi" name="citation_author"/> <meta content="Postgraduate School of Public Health" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD001416.pub5" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/07/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001416.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001416.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001416.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [administration &amp; dosage, adverse effects, *therapeutic use]; Drug Resistant Epilepsy [drug therapy]; Drug Therapy, Combination [methods]; Epilepsies, Partial [*drug therapy]; Intention to Treat Analysis; Numbers Needed To Treat; Randomized Controlled Trials as Topic; Treatment Failure; Zonisamide [administration &amp; dosage, adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001416.pub5&amp;doi=10.1002/14651858.CD001416.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001416\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001416\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ko","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001416.pub5",title:"Zonisamide add\\u2010on therapy for focal epilepsy",firstPublishedDate:"Jul 24, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001416.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001416.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001416.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001416.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001416.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001416.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001416.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001416.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001416.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001416.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1387 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001416.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full#CD001416-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full#CD001416-sec-0077"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full#CD001416-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full#CD001416-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full#CD001416-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full#CD001416-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full#CD001416-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full#CD001416-sec-0071"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/appendices#CD001416-sec-0082"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/table_n/CD001416StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/table_n/CD001416StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Zonisamide add‐on therapy for focal epilepsy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/information#CD001416-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Francesco Brigo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/information#CD001416-cr-0005">Simona Lattanzi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/information#CD001416-cr-0006">Stanley C Igwe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/information#CD001416-cr-0007">Masoud Behzadifar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001416.pub5/information#CD001416-cr-0008">Nicola Luigi Bragazzi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/information/en#CD001416-sec-0089">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 July 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001416.pub5">https://doi.org/10.1002/14651858.CD001416.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001416-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001416-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001416-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001416-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001416-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001416-abs-0004">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001416-abs-0001" lang="en"> <section id="CD001416-sec-0001"> <h3 class="title" id="CD001416-sec-0001">Background</h3> <p>The majority of people with epilepsy have a good prognosis, and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop dug‐resistant epilepsy, especially those with focal seizures. In this review, we summarised the evidence from randomised controlled trials (RCT) of zonisamide, used as an add‐on treatment for focal epilepsy uncontrolled by one or more concomitant antiepileptic drug. </p> <p>This is an updated version of the Cochrane review previously published in 2018.</p> </section> <section id="CD001416-sec-0002"> <h3 class="title" id="CD001416-sec-0002">Objectives</h3> <p>To evaluate the efficacy and tolerability of zonisamide, when used as an add‐on treatment for people with focal epilepsy uncontrolled by one or more concomitant antiepileptic drugs. </p> </section> <section id="CD001416-sec-0003"> <h3 class="title" id="CD001416-sec-0003">Search methods</h3> <p>For the latest update, we searched the Cochrane Register of Studies (CRS Web) and MEDLINE Ovid (September 2019). In addition, we contacted Eisai Limited (makers and licensees of zonisamide) and experts in the field, to seek any ongoing or unpublished studies. </p> </section> <section id="CD001416-sec-0004"> <h3 class="title" id="CD001416-sec-0004">Selection criteria</h3> <p>Randomised controlled trials, in which add‐on zonisamide was compared with placebo or another antiepileptic drug in people with focal epilepsy, uncontrolled by one or more concomitant antiepileptic drugs. </p> </section> <section id="CD001416-sec-0005"> <h3 class="title" id="CD001416-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials for inclusion, extracted data, assessed for risk of bias using the Cochrane 'Risk of bias' tool, and assessed the certainty of the evidence, using the GRADE approach. The primary outcome was at least a 50% reduction in total seizure frequency; the secondary outcomes were (1) tolerability; and (2) adverse effects. We used an intention‐to‐treat approach for our primary analyses. We estimated summary risk ratios (RRs) for each outcome. We displayed a summary of the estimates of effects and certainty of the evidence for each outcome in a 'Summary of findings' table. </p> </section> <section id="CD001416-sec-0006"> <h3 class="title" id="CD001416-sec-0006">Main results</h3> <p>We did not find any new studies since the last version of this review. We included eight studies (1636 participants) from previous versions of this review. </p> <p>The overall RR with 95% confidence interval (CI) for at least a 50% reduction in seizure frequency for 300 mg to 500 mg/day of zonisamide compared to placebo was 1.90 (95% CI 1.63 to 2.22; 7 trials, 1371 participants; moderate‐certainty evidence). The RR for 50% reduction in seizure frequency compared to placebo for any dose of zonisamide (100 mg to 500 mg/day) was 1.86 (95% CI 1.60 to 2.17; 7 trials, 1429 participants; moderate‐certainty evidence). The number needed to treat for an additional beneficial outcome was six (95% CI 4.1 to 6.8). Two trials provided evidence of a dose‐response relationship for this outcome. The RR for treatment withdrawal for 300 mg to 500 mg/day of zonisamide compared to placebo was 1.59 (95% CI 1.18 to 2.13; 6 trials, 1099 participants; moderate‐certainty evidence), and for 100 mg to 500 mg/day was 1.44 (95% CI 1.08 to 1.93; 6 trials, 1156 participants; moderate‐certainty evidence). The number needed to treat for an additional harmful outcome was 15 (95% CI 9.3 to 36.7). The following adverse effects were more likely to be associated with zonisamide than with placebo: ataxia (RR 3.85, 99% CI 1.36 to 10.93; 4 trials, 734 participants; low‐certainty evidence); somnolence (RR 1.52, 99% CI 1.00 to 2.31; 8 trials, 1636 participants; moderate‐certainty evidence); agitation (RR 2.35, 99% CI 1.05 to 5.27; 4 trials, 598 participants; low‐certainty evidence); and anorexia (RR 2.74, 99% CI 1.64 to 4.60; 6 trials, 1181 participants; low‐certainty evidence). </p> <p>Across the eight studies, we rated risk of bias domains at low or unclear risk of bias, apart from two studies, which we rated at high risk of attrition bias. Five of the eight studies were sponsored by the drug companies that produced zonisamide. </p> </section> <section id="CD001416-sec-0007"> <h3 class="title" id="CD001416-sec-0007">Authors' conclusions</h3> <p>When used as an add‐on treatment in people with focal epilepsy, uncontrolled by one or more concomitant antiepileptic drugs, moderate‐certainty evidence found that zonisamide was more successful than placebo at reducing the frequency of seizures by at least 50%. We were unable to identify minimum effective and maximum tolerated doses. The included trials evaluated a maximum stable‐dose phase of 18 weeks, so results cannot be used to confirm longer periods of efficacy in seizure control. The results cannot be extrapolated to monotherapy, or to people with other seizure types or epilepsy syndromes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001416-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001416-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001416-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001416-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001416-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001416-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001416-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001416-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001416-abs-0003">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001416-abs-0002" lang="en"> <h3>Zonisamide add‐on for focal epilepsy that does not respond to other medication</h3> <p><b>Background</b> </p> <p>Around 70% of people with epilepsy can become seizure‐free with antiepileptic drug treatment. The remaining 30% of people with epilepsy may not respond to antiepileptic drugs, and may still experience seizures. Older drugs do not prevent seizures for everyone, and they have side effects. New drugs have been developed to try to treat people who do not respond to the older drugs, and to try to limit the side effects. These newer drugs may be taken along with the person's existing medication, as an 'add‐on' treatment. </p> <p><b>Key results</b> </p> <p>Searches of six databases found eight randomised controlled trials (1636 participants), which compared the addition of the antiepileptic drug zonisamide to one or more antiepileptic drugs to a placebo, for a period of 12 weeks, in people with uncontrolled focal epilepsy. </p> <p>Taking all the evidence of the trials into account, we found that seizure frequency was reduced for people with focal epilepsy if zonisamide was added to their usual treatment. Participants treated with 300 mg to 500 mg/day of zonisamide were twice as likely as people given placebo tablets in addition to their usual treatment, to experience at least a 50% reduction in the frequency of their seizures. However, adding zonisamide to their usual treatment was associated with an increase in side effects, such as problems with co‐ordination (ataxia), drowsiness (somnolence), agitation, and poor appetite (anorexia). </p> <p><b>Certainty of the evidence</b> </p> <p>We assessed that the risk of bias within the individual trials was low, or we did not have enough information to decide. Five of the eight studies were sponsored by the drug companies that produce zonisamide. We rated the certainty of the evidence for the main outcomes as moderate. Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. More research is needed that concentrates on examining the response of different doses of zonisamide. </p> <p>The evidence is current to September 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001416-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001416-sec-0077"></div> <h3 class="title" id="CD001416-sec-0078">Implications for practice</h3> <section id="CD001416-sec-0078"> <p>People with focal epilepsy uncontrolled by one or more concomitant antiepileptic drugs were twice as likely to experience at least a 50% reduction in the frequency of their seizures when they took 300 mg to 500 mg/day of zonisamide compared to a placebo, and were treated over a stable‐dose period of up to 18 weeks. For the participants entered into the trials, approximately six participants needed to be treated with zonisamide for every additional participant with a 50% response, compared to placebo, i.e. for the population recruited into the trials, the number needed to treat for an additional beneficial outcome was six. </p> <p>Ataxia, somnolence, agitation, and anorexia were the most common and statistically significant adverse effects attributable to zonisamide. Participants treated with zonisamide were more likely to withdraw from treatment. For the participants entered into the trials, approximately 15 needed to be treated with zonisamide for every additional participant to withdraw, compared to placebo, i.e. for the population recruited into the trials, the number needed to treat for an additional harmful outcome was 15. </p> </section> <h3 class="title" id="CD001416-sec-0079">Implications for research</h3> <section id="CD001416-sec-0079"> <p>There is a need for studies that more adequately explore the dose‐response relationship for zonisamide in focal epilepsy. Zonisamide should be compared to new and standard antiepileptic drugs as both add‐on and monotherapy. With regards to the design of trials, thought should be given to the dynamics of the baseline period in order to prevent over‐estimating the efficacy of the drug. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001416-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001416-sec-0008"></div> <div class="table" id="CD001416-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Zonisamide compared to placebo for focal epilepsy</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Zonisamide compared to placebo for focal epilepsy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with focal epilepsy<br/><b>Setting:</b> hospital outpatients<br/><b>Intervention:</b> add‐on zonisamide<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with zonisamide</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>50% responder rate</b> </p> <p><i>(whole treatment period; any dose</i>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.86<br/>(95% CI 1.60 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1429<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Zonisamide 300 mg to 500 mg/day (RR 1.90, 95% CI 1.63 to 2.22; moderate‐certainty evidence) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>461 per 1000<br/>(396 to 537) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawal rates</b> </p> <p><i>(whole treatment period; any dose)</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.44<br/>(95% CI 1.08 to 1.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1156<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Zonisamide 300 mg to 500 mg/day (RR 1.59, 95% CI 1.18 to 2.13; moderate‐certainty evidence) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000<br/>(119 to 213) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: ataxia</b> </p> <p><i>(whole treatment period; any dose</i>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.85<br/>(99% CI 1.36 to 10.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>734<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Note that for adverse events, we used a 99% CI.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000<br/>(24 to 189) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: dizziness</b> </p> <p><i>(whole treatment period; any dose</i>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/>(99% CI 0.90 to 2.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1429<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000<br/>(68 to 164) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: fatigue</b> </p> <p><i>(whole treatment period; any dose</i>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.41<br/>(99% CI 0.79 to 2.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1045<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000<br/>(43 to 137) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: nausea</b> </p> <p><i>(whole treatment period; any dose</i>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10<br/>(99% CI 0.58 to 2.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>805<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<br/>(38 to 139) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: somnolence</b> </p> <p><i>(whole treatment period; any dose</i>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.52<br/>(99% CI 1.00 to 2.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1636<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000<br/>(72 to 166) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The assumed control risk (ACR) was calculated using median control group risk across the studies that provided data for that outcome.. The corresponding intervention risk in the zonisamide group (and its 95% CI) was based on the assumed risk in the comparison group (ACR) and the relative effect of the intervention (and its 95% CI) and is calculated according to following formula: corresponding intervention risk, per 100 = 100 * ACR * RR. </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty.</b>  We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty.</b>  We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty.</b>  Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for methodological uncertainties in included studies (unclear risk of bias). Some studies were at high risk of attrition bias; they did not provide reasons for differences between the number of patients in ITT and in per protocol set (PPS). However, the conclusions were unchanged following best‐case (RR 2.22, 95% CI 1.92 to 2.57) and worst‐case (RR 1.44, 95% CI 1.26 to 1.64) scenario analysis. <br/><sup>b</sup>Downgraded once for imprecision </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001416-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001416-sec-0009"></div> <p>This is an update to the Cochrane review that was originally published in 2002 (<a href="./references#CD001416-bbs2-0037" title="ChadwickDW , MarsonAG . Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews2002, Issue 2. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416]">Chadwick 2002</a>), and last updated in 2018 (<a href="./references#CD001416-bbs2-0035" title="BrigoF , LattanziS , IgweSC , BehzadifarM , BragazziNL . Zonisamide add-on therapy for focal epilepsy. Cochrane Database of Systematic Reviews2018, Issue 10. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416.pub4]">Brigo 2018</a>). </p> <p>Standard antiepileptic drugs (AEDs: e.g. carbamazepine, phenytoin, valproate) cause a number of side effects, and do not control all of a person's seizures. Therefore, over the past 15 to 20 years, there has been renewed interest in the development of new AEDs. Several new AEDs are now licensed for use in a variety of countries as an 'add‐on' treatment: felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, vigabatrin, zonisamide, eslicarbazepine acetate, perampanel, and brivaracetam. </p> <p>In this review, we investigated the efficacy and tolerability of add‐on zonisamide in people with focal epilepsy, uncontrolled by one or more concomitant antiepileptic drugs. We included people with focal epilepsy (defined as having focal onset seizures, i.e. simple focal, complex focal, secondary generalised tonic‐clonic seizures, or a combination), which had failed to respond to monotherapy with a standard AED. </p> <section id="CD001416-sec-0010"> <h3 class="title" id="CD001416-sec-0010">Description of the condition</h3> <p>Epilepsy is a common neurological condition, with an estimated incidence of 50 per 100,000, and prevalence of 5 to 10 per 1000 in the developed world (<a href="./references#CD001416-bbs2-0028" title="SanderJW , ShorvonSD . Epidemiology of the epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry1996;61(5):433-43.">Sander 1996</a>). Between two and three per cent of the population will be given a diagnosis of epilepsy at some time in their lives, the majority of whom will go into remission. However, up to 30% will fail to respond to monotherapy, often requiring treatment with a combinations of AEDs (<a href="./references#CD001416-bbs2-0015" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet1995;346:140-4.">Cockerell 1995</a>; <a href="./references#CD001416-bbs2-0016" title="HauserWA , AnnegersJF , KurlandLT . Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 - 1984. Epilepsia1993;34:453-68.">Hauser 1993</a>). These individuals will often experience significant adverse psychological and quality of life outcomes, due to continued and unpredictable seizures, side effects of drugs, and reduced educational and employment prospects. </p> </section> <section id="CD001416-sec-0011"> <h3 class="title" id="CD001416-sec-0011">Description of the intervention</h3> <p>In the majority of cases, epilepsy is treated with AEDs. These AEDs have varying mechanisms of action, and certain AEDs are more effective at treating specific seizure types. For example, carbamazepine is more effective for focal seizures (<a href="./references#CD001416-bbs2-0022" title="MarsonAG , WilliamsonPR , HuttonJL , CloughHE , ChadwickDW . Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews2000, Issue 3. Art. No: CD001030. [DOI: 10.1002/14651858.CD001030]">Marson 2000</a>), and valproate is more effective for generalised onset seizures (<a href="./references#CD001416-bbs2-0024" title="MarsonA , Al-KharusiA , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000-15.">Marson 2007</a>). Conventional first‐line drugs include carbamazepine, lamotrigine, and sodium valproate, which have a broad therapeutic effect, but are associated with a number of adverse effects. In cases where monotherapy fails to induce seizure remission, AED 'add‐on therapy' may be used in an attempt to improve seizure control. Zonisamide is one such add‐on therapy. Zonisamide is a synthetic 1,2‐benzisoxazole‐3‐methanesulfonamide with anticonvulsant properties (<a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>). Zonisamide has a long half‐life (63 to 69 hours), and the typical maintenance dose in adults over the age of 18 is 300 mg to 500 mg/day, possibly split into two doses per day (<a href="./references#CD001416-bbs2-0013" title="BaulacM , LeppikIE . Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Research2007;75:75-83.">Baulac 2007</a>; <a href="./references#CD001416-bbs2-0014" title="British National Formulary (BNF). www.bnf.org (accessed May 2013).">BNF 2013</a>). </p> </section> <section id="CD001416-sec-0012"> <h3 class="title" id="CD001416-sec-0012">How the intervention might work</h3> <p>Proposed neuropharmacological mechanisms of action for zonisamide include the blockade of voltage‐sensitive sodium channels, voltage‐dependent T‐type calcium channels, and potassium‐evoked glutamate response, reduced glutamate‐mediated synaptic excitation, and increased synaptic concentration of gamma‐aminobutyric acid (GABA; <a href="./references#CD001416-bbs2-0021" title="LeppikIE . Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure2004;S13:S5-9.">Leppik 2004</a>; <a href="./references#CD001416-bbs2-0032" title="UedaY , DoiT , TokumaruJ , WillmoreLJ . Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Molecular Brain Research2003;116(1-2):1-6.">Ueda 2003</a>). It has been proposed that zonisamide might help patients who are resistant to other AEDs, because it blocks both voltage‐sensitive sodium and T‐type calcium channels (<a href="./references#CD001416-bbs2-0021" title="LeppikIE . Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure2004;S13:S5-9.">Leppik 2004</a>). Although zonisamide does not induce liver enzymes, it is metabolised by cytochrome P450. Therefore, concomitant AEDs, which are liver enzyme‐inducing, will enhance zonisamide metabolism, so the zonisamide dosage strategy may need to be adjusted to compensate for the effect of other AEDs (<a href="./references#CD001416-bbs2-0021" title="LeppikIE . Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure2004;S13:S5-9.">Leppik 2004</a>). By scavenging hydroxyl and nitric oxide free radicals, zonisamide may also be neuroprotective (<a href="./references#CD001416-bbs2-0026" title="MoriA , NodaY , PackerL . The anticonvulsant zonisamide scavenges free radicals. Epilepsy Research1998;30:153-8.">Mori 1998</a>). </p> </section> <section id="CD001416-sec-0013"> <h3 class="title" id="CD001416-sec-0013">Why it is important to do this review</h3> <p>While the majority of people with epilepsy do respond to AEDs, a treatment solution must be found for the 30% who do not. This review update aimed to inform clinical practitioners of the efficacy and tolerability of zonisamide, when used as add‐on therapy to treat people with focal epilepsy who were experiencing seizures, despite the use of one or more concomitant antiepileptic drugs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001416-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001416-sec-0014"></div> <p>To evaluate the efficacy and tolerability of zonisamide, when used as an add‐on treatment for people with focal epilepsy, uncontrolled by one or more concomitant antiepileptic drug. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001416-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001416-sec-0015"></div> <section id="CD001416-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001416-sec-0017"> <h4 class="title">Types of studies</h4> <p> <ol id="CD001416-list-0001"> <li> <p>Randomised controlled trials (RCT), in which an adequate method of concealment of randomisation was used (e.g. allocation of sequentially numbered, sealed packages of medication, sealed opaque envelopes, telephone randomisation) </p> </li> <li> <p>Double‐blind trials, in which both participant and clinician treating or assessing the outcome, were blinded to treatment allocation </p> </li> <li> <p>Placebo‐controlled or head‐to‐head drug trials where zonisamide was compared directly to another add‐on AED </p> </li> <li> <p>Parallel‐group or cross‐over studies</p> </li> <li> <p>Minimum treatment period of eight weeks. This period was selected as it represents the minimum time over which changes in seizure frequency can be determined, given the propensity of seizures to occur in clusters. </p> </li> <li> <p>We would have excluded studies using a response conditional design, however, none were found. In this type of study, participants are given active treatment during a pre‐randomisation baseline period, and only those having a pre‐defined response to treatment are allocated to treatment groups. We decided to exclude this type of trial as they are really evaluating the effect of drug withdrawal in a highly selected population of individuals. In addition, there is no drug‐free baseline from which a reduction in seizure frequency can be calculated. </p> </li> </ol> </p> </section> <section id="CD001416-sec-0018"> <h4 class="title">Types of participants</h4> <p>Participants of any age with focal epilepsy (i.e. experiencing simple focal, complex focal, or secondary generalised tonic‐clonic seizures), uncontrolled by one or more concomitant antiepileptic drug. </p> </section> <section id="CD001416-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD001416-list-0002"> <li> <p>The active treatment group received treatment with zonisamide in addition to conventional AED treatment. </p> </li> <li> <p>The control group received matched placebo in addition to conventional AED treatment.</p> </li> </ol> </p> </section> <section id="CD001416-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD001416-sec-0021"> <h5 class="title">Primary outcomes</h5> <section id="CD001416-sec-0022"> <h6 class="title">Efficacy</h6> <p>Proportion of participants with a 50% or greater reduction in seizure frequency in the treatment period compared to the pre‐randomisation baseline period. We chose this outcome as it is commonly reported in this type of study, and can be calculated for studies that do not report this outcome, provided that baseline seizure data were recorded. </p> </section> </section> <section id="CD001416-sec-0023"> <h5 class="title">Secondary outcomes</h5> <section id="CD001416-sec-0024"> <h6 class="title">Tolerability</h6> <p>The proportion of participants who withdrew from treatment during the course of the treatment period was used as a measure of global tolerability. Treatment is likely to be withdrawn due to adverse effects, lack of efficacy, or a combination of both, and this is an outcome to which participants can make a direct contribution. In trials of short duration, it is likely that adverse effects will be the most common reason for withdrawal. </p> </section> <section id="CD001416-sec-0025"> <h6 class="title">Adverse effects</h6> <p> <ol id="CD001416-list-0003"> <li> <p>The proportion of participants experiencing any of the following five adverse effects, which were found, through research, to be common and important adverse effects of AEDs: </p> <ol id="CD001416-list-0004"> <li> <p>ataxia;</p> </li> <li> <p>dizziness;</p> </li> <li> <p>fatigue;</p> </li> <li> <p>nausea;</p> </li> <li> <p>somnolence.</p> </li> </ol> </li> <li> <p>The proportion of participants experiencing the five most common adverse effects, if different from those listed above. </p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD001416-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001416-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We ran searches for the original review in December 1999. We ran subsequent searches in December 2001, March 2003, August 2005, July 2007, June 2010, February 2011, August 2012, February 2013, January 2016, September 2017, and September 2019. For the latest update, we searched the following databases on 17 September 2019, with no language restrictions. </p> <p> <ol id="CD001416-list-0005"> <li> <p>The Cochrane Register of Studies (CRS Web), using the search strategy outlined in <a href="./appendices#CD001416-sec-0083">Appendix 1</a>. </p> </li> <li> <p>MEDLINE Ovid (1946 to September 13, 2019), using the search strategy outlined in <a href="./appendices#CD001416-sec-0084">Appendix 2</a>. </p> </li> </ol> </p> <p>CRS Web includes randomised or quasi‐randomised, controlled trials from PubMed, EMBASE, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (ICTRP), the Cochrane Central Register of Controlled Trials (CENTRAL), and the Specialized Registers of Cochrane Review Groups, including Epilepsy. We also searched SCOPUS as a substitute for EMBASE on 13 February 2013, using the search strategy outlined in <a href="./appendices#CD001416-sec-0085">Appendix 3</a>, but this is no longer necessary, because RCTs and quasi‐RCTs in EMBASE are now included in CRS Web. </p> </section> <section id="CD001416-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We contacted Eisai Limited (makers and licensees of zonisamide) and experts in the field, to seek any ongoing or unpublished studies. </p> </section> </section> <section id="CD001416-sec-0029"> <h3 class="title" id="CD001416-sec-0029">Data collection and analysis</h3> <section id="CD001416-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Two review authors (Francesco Brigo and Simona Lattanzi) independently assessed trials for inclusion. They resolved any disagreement through discussion. </p> <p>The same two review authors extracted the following information from included trials; they resolved disagreements by consulting a third review author (Nicola Luigi Bragazzi). </p> </section> <section id="CD001416-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>We extracted the following information for each trial, using a data extraction sheet.</p> <section id="CD001416-sec-0032"> <h5 class="title">Methodological and trial design</h5> <p> <ol id="CD001416-list-0006"> <li> <p>Method of randomisation and allocation concealment</p> </li> <li> <p>Method of blinding</p> </li> <li> <p>Whether any participants had been excluded from reported analyses</p> </li> <li> <p>Duration of baseline period</p> </li> <li> <p>Duration of treatment period</p> </li> <li> <p>Dose(s) of zonisamide tested</p> </li> </ol> </p> </section> <section id="CD001416-sec-0033"> <h5 class="title">Participant and demographic information</h5> <p> <ol id="CD001416-list-0007"> <li> <p>Total number of participants allocated to each treatment group</p> </li> <li> <p>Age, sex</p> </li> <li> <p>Number with focal, generalised epilepsy</p> </li> <li> <p>Seizure types</p> </li> <li> <p>Seizure frequency during the baseline period</p> </li> <li> <p>Number of background drugs</p> </li> </ol> </p> <p>Four of the five studies found for <a href="./references#CD001416-bbs2-0036" title="CarmichaelK , PulmanJ , LakhanSE , ParikhP , MarsonAG . Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416.pub3]">Carmichael 2013</a> had been sponsored by Eisai (no source of funding was used to assist in the conduct of the <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a> trial). They supplied copies of internal trial reports, which we used to confirm the following information. </p> <p> <ol id="CD001416-list-0008"> <li> <p>The method of randomisation</p> </li> <li> <p>The total number randomised to each group</p> </li> <li> <p>The number of people in each group achieving a 50% or greater reduction in seizure frequency per treatment group </p> </li> <li> <p>The number of people having treatment withdrawn post‐randomisation per treatment group</p> </li> <li> <p>For those excluded:</p> <ol id="CD001416-list-0009"> <li> <p>the reason for exclusion;</p> </li> <li> <p>whether any of those excluded completed the treatment phase;</p> </li> <li> <p>whether any of those excluded had a 50% or greater reduction in seizure frequency during the treatment phase. </p> </li> </ol> </li> </ol> </p> </section> <section id="CD001416-sec-0034"> <h5 class="title">Outcomes</h5> <p>We recorded the number of participants experiencing each outcome (see <a href="#CD001416-sec-0020">Types of outcome measures</a>) per randomised group. </p> </section> </section> <section id="CD001416-sec-0035"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (Francesco Brigo and Simona Lattanzi) independently assessed risk of bias for each of the eight included trials using the Cochrane 'Risk of bias' tool, found in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001416-bbs2-0018" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). A third party resolved disagreements in the assessment of the level of bias. We extracted data from the eight included studies relating to sequence generation, concealment of allocation, methods of blinding, incomplete outcome data, selective reporting, and other types of bias. We made a judgement of the level of bias involved for each of these categories for all included studies. </p> </section> <section id="CD001416-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <p>We presented the outcomes 50% or greater reduction in seizure frequency, treatment withdrawal, and adverse effects as risk ratios (RR). </p> </section> <section id="CD001416-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>There were no special issues to consider with the design of the included studies. All included studies used a parallel design, six with a stable‐dose phase of 12 weeks (<a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>; <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>; <a href="./references#CD001416-bbs2-0003" title="GuerriniR , RosatiA , SegiethJ , PellacaniS , BradshawK , GiorgiL . A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia2013;54(8):1473-80. ">Guerrini 2013</a>; <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>; <a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>; <a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a>), one with a stable‐phase of 13 weeks (<a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a>), and one with a stable‐dose phase of 18 weeks (<a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a>). </p> </section> <section id="CD001416-sec-0038"> <h4 class="title">Dealing with missing data</h4> <p>We conducted intention‐to‐treat, best‐case, and worst‐case analyses to account for any missing data. </p> </section> <section id="CD001416-sec-0039"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by evaluating similarities of the participants and interventions, as well as the outcomes measured in the included studies, and assessed methodological heterogeneity by evaluating variability in study design and risk of bias. We evaluated statistical heterogeneity by visually inspecting forest plots. We assessed statistical heterogeneity using the Chi² test and I² statistic, according to section 9.5.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001416-bbs2-0018" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>): 0% to 40% might not be important, 30% to 60% may represent moderate heterogeneity, 50% to 90% may represent substantial heterogeneity, and 75% to 100% indicated considerable heterogeneity. </p> <p>Our intention was to use a fixed‐effect model if we did not find statistically significant heterogeneity between the included studies. If statistical heterogeneity had been present, we would have used a random‐effects model. </p> </section> <section id="CD001416-sec-0040"> <h4 class="title">Assessment of reporting biases</h4> <p>We contacted authors of all included studies and requested trial protocols, in order to identify any discrepancies between protocol and trial methodology. </p> </section> <section id="CD001416-sec-0041"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effect model to synthesise the collected data. Planned comparisons and outcomes included: </p> <p> <ol id="CD001416-list-0010"> <li> <p>50% or greater reduction in seizure frequency in the intervention group versus the control group; </p> </li> <li> <p>treatment withdrawal rates in the intervention group versus the control group;</p> </li> <li> <p>adverse effects in the intervention group versus the control group.</p> </li> </ol> </p> <p>The preferred estimator was the Mantel‐Haenszel risk ratio (RR). We used 95% confidence intervals (CIs) for the 50% or greater reduction in seizure frequency, and treatment withdrawal outcomes. We used 99% CI for the adverse effects outcomes. All analyses included all participants in the groups to which they had been allocated. </p> <p>For the 50% or greater reduction in seizure frequency, and for the tolerability outcomes, we computed the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH), according to methods reported in <a href="./references#CD001416-bbs2-0030" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al, Cochrane Applicability and Recommendations Methods Group. Chapter 12 Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011</a>. </p> <section id="CD001416-sec-0042"> <h5 class="title">For the 50% or greater reduction in seizure frequency outcome, we conducted three analyses: </h5> <section id="CD001416-sec-0043"> <h6 class="title">1. Primary analysis (intention‐to‐treat)</h6> <p>We assumed that participants not completing follow‐up, or with inadequate seizure data, were non‐responders. </p> </section> <section id="CD001416-sec-0044"> <h6 class="title">2. Worst‐case analysis</h6> <p>We assumed that participants not completing follow‐up, or with inadequate seizure data, were non‐responders in the zonisamide group and responders in the control group. The worst‐case scenario assumes missing participants in the control group had good outcomes and those in the experimental group had bad outcomes (<a href="./references#CD001416-bbs2-0017" title="HigginsJP , WhiteIR , WoodAM . Imputation methods for missing outcome data in meta-analysis of clinical trials. Clinical Trials2008;5(3):225-39.">Higgins 2008</a>). </p> </section> <section id="CD001416-sec-0045"> <h6 class="title">3. Best‐case analysis</h6> <p>We assumed that participants not completing follow‐up, or with inadequate seizure data, were responders in the zonisamide group and non‐responders in the control group. The best‐case scenario assumes missing participants in the experimental group had good outcomes and those in the control group had bad outcomes (<a href="./references#CD001416-bbs2-0017" title="HigginsJP , WhiteIR , WoodAM . Imputation methods for missing outcome data in meta-analysis of clinical trials. Clinical Trials2008;5(3):225-39.">Higgins 2008</a>). </p> </section> </section> <section id="CD001416-sec-0046"> <h5 class="title">Dose‐regression analysis</h5> <p>We had planned to examine dose‐response relationships using logistic regression, in the framework of generalised linear models (<a href="./references#CD001416-bbs2-0025" title="McCullaghP , NelderJA . Generalized Linear Models. Second edition. London: Chapman and Hall, 1989.">McCullagh 1989</a>).  We were unable to use this approach due to the structure of the data in the trials. Hence, we simply provided the results for each dose compared to control. </p> </section> </section> <section id="CD001416-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted subgroup analysis for adverse effects data and produced risk ratios for each different adverse effect. We also conducted subgroup analysis for mg/day dose of zonisamide. </p> </section> <section id="CD001416-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>If we had found trial methodologies to be sufficiently distinct, we would have conducted sensitivity analyses to identify which factor(s) were influential in the degree of heterogeneity. </p> </section> <section id="CD001416-sec-0049"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the GRADE Handbook, to assess the certainty of evidence for the primary and secondary outcomes (<a href="./references#CD001416-bbs2-0031" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). We included data on the following outcomes for any dose, measured for the whole treatment period: 50% responder rate; withdrawal rates; ataxia; dizziness; fatigue; nausea; and somnolence. </p> <p>We presented this information in a 'Summary of findings' table (see <a href="./full#CD001416-tbl-0001">summary of findings Table 1</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001416-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001416-sec-0050"></div> <section id="CD001416-sec-0051"> <h3 class="title">Description of studies</h3> <section id="CD001416-sec-0052"> <h4 class="title">Results of the search</h4> <p>The update of searches for this review yielded 22 results; 18 from the Cochrane Register of Studies (CRS Web; 13 September 2010), and four from MEDLINE (1946 to September 13, 2019). After removing five duplicates and one obviously irrelevant item, we identified 16 articles for possible inclusion. On further evaluation of titles and abstracts, none of these articles met the inclusion criteria (<a href="#CD001416-fig-0001">Figure 1</a>). Hence, review authors found no additional studies for inclusion in this updated version of this review. </p> <div class="figure" id="CD001416-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="This diagram refers only to results of the updated searches for the current version of the review" data-id="CD001416-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>This diagram refers only to results of the updated searches for the current version of the review </p> </div> </div> </div> <p>Searches from previous versions of this review identified eight studies that met the inclusion criteria (<a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>; <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>; <a href="./references#CD001416-bbs2-0003" title="GuerriniR , RosatiA , SegiethJ , PellacaniS , BradshawK , GiorgiL . A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia2013;54(8):1473-80. ">Guerrini 2013</a>; <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a>; <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>; <a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>; <a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a>; <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a>). A full report for one study was unobtainable, so it was identified as awaiting classification (<a href="./references#CD001416-bbs2-0010" title="AndersonTJ , DonaldsonIM , McConnellH , PollockM , DobbsBR . Zonisamide: comparison with sodium valproate as additional treatment in refractory seizures. New Zealand Medical Journal1988;101(854):611. ">Anderson 1988</a>). We also found two unpublished studies in the last update of this review (<a href="./references#CD001416-bbs2-0035" title="BrigoF , LattanziS , IgweSC , BehzadifarM , BragazziNL . Zonisamide add-on therapy for focal epilepsy. Cochrane Database of Systematic Reviews2018, Issue 10. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416.pub4]">Brigo 2018</a>); however, a full report of them was not available, so both were identified as awaiting classification (<a href="./references#CD001416-bbs2-0011" title="NCT00327717. Evaluating the efficacy and safety of zonisamide in the treatment of partial seizures. clinicaltrials.gov/ct2/show/NCT00327717 (first posted 18 May 2006). ">NCT00327717</a>; <a href="./references#CD001416-bbs2-0012" title="NCT01546688. A study to evaluate the safety and tolerability and explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial seizures. clinicaltrials.gov/ct2/show/NCT01546688 (first posted 7 March 2012). ">NCT01546688</a>). </p> </section> <section id="CD001416-sec-0053"> <h4 class="title">Included studies</h4> <p>The eight studies (1636 participants) already included in the previous versions of this review were parallel‐group trials with a stable‐dose phase of 12 or 18 weeks (although <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a> added a cross‐over phase for all participants in the final five weeks, only the parallel group data were included in analysis (<a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>; <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>; <a href="./references#CD001416-bbs2-0003" title="GuerriniR , RosatiA , SegiethJ , PellacaniS , BradshawK , GiorgiL . A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia2013;54(8):1473-80. ">Guerrini 2013</a>; <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a>; <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>; <a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>; <a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a>; <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a>). Two studies allowed some dose titration according to seizure response and tolerability (<a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>; <a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>). In both studies, the median daily dose for participants completing the study was 400 mg. A third study titrated to 400 mg/day, but participants randomised to zonisamide followed different rates of titration during the first five weeks of the study, which allowed some comparison to placebo, 100 mg/day, and 200 mg/day during this period of the study (<a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>). <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a> randomised participants to placebo, 100 mg, 300 mg, or 500 mg of zonisamide in a 2:1:1:2 ratio, allowing further investigation of dose‐response relationships.  <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a> used two different titration strategies; in the first, a 100 mg/day zonisamide dose was given for the first two weeks after baseline, 200 mg/day for the third week, and 300 mg/day from week four onwards. The initial dose in the second strategy was 100 mg/day of zonisamide, increasing weekly by increments of 100 mg/day until a target of 400 mg/day was reached in week four, and continued for the duration of the trial. <a href="./references#CD001416-bbs2-0003" title="GuerriniR , RosatiA , SegiethJ , PellacaniS , BradshawK , GiorgiL . A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia2013;54(8):1473-80. ">Guerrini 2013</a> titrated zonisamide in weekly increments of 1 mg/kg/day over eight weeks, to a target dose of 8 mg/kg/day (max 500 mg/day), and continued unchanged over the 12‐week maintenance period. <a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a> titrated zonisamide as follows: first two weeks 100 mg/day, third week 200 mg/day, and fourth week 300 mg/day, which was maintained to the end, although, according to the participants's situation, doses could be increased to 400mg/day. In the last study, <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a> started zonisamide at 100 mg/day, and then increased to 300 mg/day (100 mg, three times a day) within three weeks; the dose during maintenance was 300 mg/day. </p> <p>See <a href="./references#CD001416-sec-0095" title="">Characteristics of included studies</a> for full details of the included studies. </p> </section> <section id="CD001416-sec-0054"> <h4 class="title">Excluded studies</h4> <p>None of the 16 articles obtained by the updated search strategy appeared to meet the eligibility criteria, and therefore, we considered them not relevant (see <a href="#CD001416-sec-0052">Results of the search</a>). </p> <p>In previous versions of this review, the review authors excluded <a href="./references#CD001416-bbs2-0009" title="ShimizuA , YamamotoJ , YamadaY , TanakaM , KawasakiT . The antiepileptic effect of zonisamide on patients with refractory seizures and its side effects. Japanese Journal of Psychiatry and Neurology1988;42(3):583. ">Shimizu 1988</a>, as no control group was used (see <a href="./references#CD001416-sec-0096" title="">Characteristics of excluded studies</a>; <a href="./references#CD001416-bbs2-0035" title="BrigoF , LattanziS , IgweSC , BehzadifarM , BragazziNL . Zonisamide add-on therapy for focal epilepsy. Cochrane Database of Systematic Reviews2018, Issue 10. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416.pub4]">Brigo 2018</a>; <a href="./references#CD001416-bbs2-0036" title="CarmichaelK , PulmanJ , LakhanSE , ParikhP , MarsonAG . Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416.pub3]">Carmichael 2013</a>; <a href="./references#CD001416-bbs2-0037" title="ChadwickDW , MarsonAG . Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews2002, Issue 2. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416]">Chadwick 2002</a>; <a href="./references#CD001416-bbs2-0038" title="ChadwickDW , MarsonAG . Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416.pub2]">Chadwick 2005</a>). </p> <section id="CD001416-sec-0055"> <h5 class="title">Studies awaiting classification</h5> <p>One add‐on study that met the inclusion criteria compared zonisamide with valproate rather than placebo in a head‐to‐head trial (<a href="./references#CD001416-bbs2-0010" title="AndersonTJ , DonaldsonIM , McConnellH , PollockM , DobbsBR . Zonisamide: comparison with sodium valproate as additional treatment in refractory seizures. New Zealand Medical Journal1988;101(854):611. ">Anderson 1988</a>). However, only a single‐page summary was available, which gave too little information on methods or outcome data. Two further studies compared add‐on zonisamide with placebo; however, at the time when this latest update of the review was performed, a full report of these studies was not available (<a href="./references#CD001416-bbs2-0011" title="NCT00327717. Evaluating the efficacy and safety of zonisamide in the treatment of partial seizures. clinicaltrials.gov/ct2/show/NCT00327717 (first posted 18 May 2006). ">NCT00327717</a>; <a href="./references#CD001416-bbs2-0012" title="NCT01546688. A study to evaluate the safety and tolerability and explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial seizures. clinicaltrials.gov/ct2/show/NCT01546688 (first posted 7 March 2012). ">NCT01546688</a>). Therefore, we are still currently unable to include information from these trials in the review (see <a href="./references#CD001416-sec-0097" title="">Characteristics of studies awaiting classification</a>). </p> </section> </section> </section> <section id="CD001416-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD001416-fig-0002">Figure 2</a> for a summary of the risk of bias in the included studies. </p> <div class="figure" id="CD001416-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD001416-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> <section id="CD001416-sec-0057"> <h4 class="title">Allocation</h4> <p>In three studies, allocation was concealed by dispensing sequentially numbered packages to each participant (<a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>; <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>; <a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>), whilst <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a> used a telephone randomisation service. In two studies, participants were assigned to groups in blocks of six (<a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>), and four (<a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>). Randomisation codes were generated centrally (<a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>), or by the study sponsor (<a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>). <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a> used a process of restricted randomisation as zonisamide and placebo were assigned in a ratio of 1:1. </p> <p>Participant codes were hidden by use of numbered containers (<a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a>; <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>), or sealed envelopes containing an individual participant code (<a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>). However, the appearance of the items used to conceal codes was not explicitly described, so one could not be certain how effective these concealment methods were. One study performed randomisation using a stratified random, segmented random, and random distribution list (<a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a>). Allocation concealment and random sequence generation were not specified in one study (<a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a>). </p> </section> <section id="CD001416-sec-0058"> <h4 class="title">Blinding</h4> <p>We deemed six of the included studies to be at low risk of performance bias (participants), as placebo and zonisamide tablets were identical in appearance (<a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>; <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>; <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a>; <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>; <a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>; <a href="./references#CD001416-bbs2-0003" title="GuerriniR , RosatiA , SegiethJ , PellacaniS , BradshawK , GiorgiL . A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia2013;54(8):1473-80. ">Guerrini 2013</a>). Two studies did not specify whether placebo and zonisamide tablets were identical in appearance (<a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a>; <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a>). </p> <p>Blinding of outcome assessors was not detailed in any of the included studies, and therefore, we classified this as being at an unclear risk of bias. However, participants self‐reported seizure frequency and duration, and therefore, we thought that a lack of detail on the outcome assessors would have a minimal impact overall. One trial report did not provide any detail with regard to blinding of study personnel or outcome assessors, and as such, we classified it as being at unclear risk of bias overall (<a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>). </p> </section> <section id="CD001416-sec-0059"> <h4 class="title">Incomplete outcome data</h4> <p>We classified <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a> and <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a> to be at a low risk of attrition bias overall, as few participants left the study before completion for any reason, and those who did were reasonably evenly spread across the different intervention groups. We assessed <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a> to be at an unclear risk of attrition bias, due to unclear reporting of missing data and study attrition rates. <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a> did not clearly report all data in relation to study attrition and missing data. The attrition rate was not clearly reported in <a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>, and as such, we classified it as being at an unclear risk of attrition bias. Two studies were at high risk of attrition bias(<a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a>; <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a>). </p> <p>All of the trials conducted a modified version of an intention‐to‐treat (ITT) analysis, while one trial also conducted a second, unmodified ITT analysis (<a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>). Three trials failed to include all randomised participants in their ITT analysis, and instead omitted participants who had not completed the trial for any reason (<a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>; <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a>; <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>). In these three trials, participants were included in the ITT analysis if they had taken at least one dose of the intervention to which they had been allocated. A fourth trial also conducted a modified ITT analysis, but instead, included participants who had received at least seven days of treatment (<a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>). </p> </section> <section id="CD001416-sec-0060"> <h4 class="title">Selective reporting</h4> <p>We contacted all study authors; some provided additional data, but nobody made their trial protocols available to us. All primary and secondary outcomes outlined in the methods section of each trial were analysed and reported in the results section of each study, so we classified them as being at a low risk of reporting bias. </p> </section> <section id="CD001416-sec-0061"> <h4 class="title">Other potential sources of bias</h4> <p>One potential source of other bias would be the unequal duration of stable‐dose phase, depending on to which dosage group a participant had been allocated. Specifically, in one study, participants allocated to the 100 mg/day zonisamide dose were on a stable dose for 23 weeks in total, as their titration phase was relatively brief in comparison to those participants in the 300 mg/day and 500 mg/day groups who had a stable‐dose phase of 20 and 18 weeks respectively (<a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>). </p> <p>Five included trials were sponsored by industry (Dainippon or Elan Pharma; <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>; <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>; <a href="./references#CD001416-bbs2-0003" title="GuerriniR , RosatiA , SegiethJ , PellacaniS , BradshawK , GiorgiL . A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia2013;54(8):1473-80. ">Guerrini 2013</a>; <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>; <a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>). No sources of funding were used to assist in the conduct or preparation of <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a>, but two different manufacturers of zonisamide provided the drug for the trial (Eisai Co. Ltd and Shenzhen Zifu Co. Ltd). Two studies did not provide details on funding (<a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a>; <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a>). Only authors of one study explicitly specified their conflicts of interest (<a href="./references#CD001416-bbs2-0003" title="GuerriniR , RosatiA , SegiethJ , PellacaniS , BradshawK , GiorgiL . A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia2013;54(8):1473-80. ">Guerrini 2013</a>). Two studies extended the baseline period by four weeks if participants did not experience 15 or more seizures in the first four weeks of baseline, or 30 or more seizures in the first eight weeks of baseline (<a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>; <a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>). This manipulation may have artificially inflated the effect of zonisamide on seizure frequency, making any reduction in seizures attributed to zonisamide of a greater magnitude by comparison. Conversely, this extension of the baseline period may have increased the likelihood of regression to the mean. We did not find evidence of any other source of bias in the remaining included trials (low risk of bias; <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>; <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>; <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a>; <a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a>; <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a>). </p> </section> </section> <section id="CD001416-sec-0062"> <h3 class="title" id="CD001416-sec-0062">Effects of interventions</h3> <p>See: <a href="./full#CD001416-tbl-0001"><b>Summary of findings 1</b> Zonisamide compared to placebo for focal epilepsy</a> </p> <section id="CD001416-sec-0063"> <h4 class="title">Zonisamide versus placebo</h4> <section id="CD001416-sec-0064"> <h5 class="title">Efficacy: 50% or greater reduction in seizure frequency</h5> <p>Seven studies with 1429 participants contributed to this outcome. Despite different titration schedules and dosages (see <a href="#CD001416-sec-0053">Included studies</a>), included studies were clinically and methodologically similar enough to warrant pooling. </p> <p>Analysis of participants who experienced a 50% or greater reduction in their seizure frequency (responders) included data from the whole treatment period (titration plus stable‐dose phase). </p> <p>There were differences in the median, target, and maximum dose across studies: median dose was 400 mg in <a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a> and <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>; the target dose was 400 mg in <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>, 300 mg in <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a>, and either 300 mg/day or 400 mg/day in <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a>; the maximum dose was 400 mg in <a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a>. <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a> tested different doses of 100 mg, 300 mg, and 500 mg. Taking into account these differences, our analyses included data from all groups in <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>, as well as analyses excluding the 100 mg/day group. </p> <p>We excluded <a href="./references#CD001416-bbs2-0003" title="GuerriniR , RosatiA , SegiethJ , PellacaniS , BradshawK , GiorgiL . A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia2013;54(8):1473-80. ">Guerrini 2013</a> from the analysis, as it did not provide data from the whole treatment period. </p> <section id="CD001416-sec-0065"> <h6 class="title">1. Whole treatment period analysis</h6> <p>For the analysis using any dose of zonisamide, there was no statistical heterogeneity among trials (I² = 0%), and the overall risk ratio (RR) was 1.86 (95% confidence interval (CI) 1.60 to 2.17; 7 RCTs, 1429 participants). Results excluding the 100 mg group from <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a> were similar (RR 1.90, 95% CI 1.63 to 2.22; 7 RCTs, 1371 participants). Number needed to treat for an additional beneficial outcome (NNTB) calculations showed that approximately six participants (95% CI 4.1 to 6.8) would need to be treated with zonisamide for every additional participant with at least a 50% response. </p> <p>Both analyses indicated a significant treatment effect (<a href="./references#CD001416-fig-0003" title="">Analysis 1.1</a>). </p> </section> <section id="CD001416-sec-0066"> <h6 class="title">2. Best‐ and worst‐case scenarios</h6> <p>We calculated best‐ and worst‐case scenarios using data for the whole treatment period, for all doses of zonisamide. For the best‐case scenario, the overall RR was 2.22 (95% CI 1.92 to 2.57; 7 RCTs, 1429 participants; <a href="./references#CD001416-fig-0004" title="">Analysis 1.2</a>), and for the worst‐case, the RR was 1.44 (95% CI 1.26 to 1.64; 7 RCTs, 1429 participants; <a href="./references#CD001416-fig-0005" title="">Analysis 1.3</a>). </p> </section> <section id="CD001416-sec-0067"> <h6 class="title">3. Results for each dose compared to placebo</h6> <p><a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a> and <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a> provided data for different doses of zonisamide. For <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>, estimates were as follows: 100 mg/day (RR 1.70, 95% CI 0.98 to 2.97; 177 participants), 300 mg/day (RR 1.94, 95% CI 1.14 to 3.31; 176 participants), and 500 mg/day (RR 2.66, 95% CI 1.73 to 4.11; 238 participants; <a href="./references#CD001416-fig-0006" title="">Analysis 1.4</a>). Estimates indicated increasing efficacy with increasing dose. For <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>, there was no clear relationship between dose and response: 100 mg/day (RR 1.93, 95% CI 0.96 to 3.91; 145 participants), 200 mg/day (RR 2.26, 95% CI 1.15 to 4.48; 143 participants), and 400 mg/day (RR 1.74, 95% CI 1.11 to 2.75; 203 participants; <a href="./references#CD001416-fig-0007" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD001416-sec-0068"> <h5 class="title">Tolerability: treatment withdrawal for any reason</h5> <p>Six studies with 1156 participants contributed to this outcome.</p> <p>We undertook analyses including and excluding the 100 mg/day group from <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>. <a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a> and <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a> did not provide data on this outcome. We could not perform an analysis excluding the 100mg/day group from <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>, as the final report of this study provided aggregate data on patients receiving 100mg/day and 200 mg/day. For both analyses, there was no statistical heterogeneity (I² = 0%). For any dose of zonisamide, the RR was 1.44 (95% CI 1.08 to 1.93; 6 RCTs, 1156 participants); and excluding the 100 mg/day group from <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>, the RR was 1.59 (95% CI 1.18 to 2.13; 6 RCTs, 1099 participants; <a href="./references#CD001416-fig-0008" title="">Analysis 1.6</a>). </p> <p>Therefore, participants receiving zonisamide were more likely to withdraw than those receiving placebo. Number needed to treat for an additional harmful (NNTH) outcome calculations showed that approximately 15 participants (95% CI 9.3 to 36.7) needed to be treated with zonisamide for every participant who withdrew, compared to placebo. </p> </section> <section id="CD001416-sec-0069"> <h5 class="title">Adverse effects</h5> <p>In addition to reports of ataxia, dizziness, fatigue, nausea, and somnolence (prespecified adverse effects; see <a href="#CD001416-sec-0023">Secondary outcomes</a>), agitation and anorexia were among the five most common adverse effects, and therefore, we included them in this analysis. </p> <p>Seven studies with 1429 participants provided data on one or more of the above mentioned adverse effects. <a href="./references#CD001416-bbs2-0003" title="GuerriniR , RosatiA , SegiethJ , PellacaniS , BradshawK , GiorgiL . A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia2013;54(8):1473-80. ">Guerrini 2013</a> did not report data on ataxia, dizziness, or agitation; <a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a> did not report data on ataxia, nausea, fatigue, or agitation; and <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a> did not report data on nausea or agitation. </p> <p>The confidence intervals for the following adverse effects results did not cross the line of no effect: ataxia (RR 3.85, 99% CI 1.36 to 10.93; P = 0.0009; 4 RCTs, 734 participants), somnolence (RR 1.52, 99% CI 1.00 to 2.31; P = 0.01; 8 RCTs, 1636 participants), agitation (RR 2.35, 99% CI 1.05 to 5.27; P = 0.07; 4 RCTs, 598 participants), and anorexia (RR 2.74, 99% CI 1.64 to 4.60; P &lt; 0.00001; 6 RCTs, 1181 participants), indicating that these effects were more likely to occur in patients receiving zonisamide than in those receiving placebo, and should probably be considered treatment‐related adverse effects. </p> <p>For the following adverse effects, the confidence interval crossed the line of no effect: dizziness (RR 1.40, 99% CI 0.90 to 2.18; P = 0.05; 7 RCTs, 1429 participants), fatigue (RR 1.41, 99% CI 0.79 to 2.53; P = 0.12; 6 RCTs, 1045 participants), and nausea (RR 1.10, 99% CI 0.58 to 2.10; P = 0.70; 5 RCTs, 805 participants; <a href="./references#CD001416-fig-0009" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD001416-sec-0070"> <h4 class="title">Zonisamide versus another antiepileptic drug</h4> <p>We did not find full reports of any studies that conducted studies on zonisamide versus another antiepileptic drug, although three potential studies are awaiting classification. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001416-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001416-sec-0071"></div> <p>When reading this updated version, please note that we changed the title of the original Cochrane Review from 'Zonisamide add‐on for drug‐resistant partial epilepsy' (<a href="./references#CD001416-bbs2-0037" title="ChadwickDW , MarsonAG . Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews2002, Issue 2. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416]">Chadwick 2002</a>; <a href="./references#CD001416-bbs2-0038" title="ChadwickDW , MarsonAG . Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416.pub2]">Chadwick 2005</a>; <a href="./references#CD001416-bbs2-0036" title="CarmichaelK , PulmanJ , LakhanSE , ParikhP , MarsonAG . Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416.pub3]">Carmichael 2013</a>), to 'Zonisamide add‐on therapy for focal epilepsy' (<a href="./references#CD001416-bbs2-0035" title="BrigoF , LattanziS , IgweSC , BehzadifarM , BragazziNL . Zonisamide add-on therapy for focal epilepsy. Cochrane Database of Systematic Reviews2018, Issue 10. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416.pub4]">Brigo 2018</a>). We used the term 'focal' according to the most recent classification of epilepsies of the International League Against Epilepsy (ILAE; <a href="./references#CD001416-bbs2-0029" title="SchefferIE , BerkovicS , CapovillaG , ConnollyMB , FrenchJ , GuilhotoL , et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia2017;58(4):512-21.">Scheffer 2017</a>). We also decided to avoid the term 'drug‐resistant epilepsy', because according to the current definition by the ILAE (<a href="./references#CD001416-bbs2-0019" title="KwanP , ArzimanoglouA , BergAT , BrodieMJ , HauserAW , MathernG , et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia2010;51(6):1069-77.">Kwan 2010</a>), it should be defined as the 'failure of adequate trials of two tolerated, appropriately chosen, and used antiepileptic drug schedules (whether as monotherapies, or in combination) to achieve sustained seizure freedom'. However, some studies included in this review were conducted in participants receiving only one background antiepileptic drug; according to the ILAE definition, these participants would not be classified as having drug‐resistant epilepsy. </p> <section id="CD001416-sec-0072"> <h3 class="title" id="CD001416-sec-0072">Summary of main results</h3> <p>In this updated version of the systematic review, we identified no additional studies for inclusion. Therefore, the conclusions of the previous updated version remain unchanged (<a href="./references#CD001416-bbs2-0035" title="BrigoF , LattanziS , IgweSC , BehzadifarM , BragazziNL . Zonisamide add-on therapy for focal epilepsy. Cochrane Database of Systematic Reviews2018, Issue 10. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416.pub4]">Brigo 2018</a>). </p> <p>The previous updated version of the review included eight studies (1636 participants). The intention‐to‐treat analysis showed that zonisamide reduced seizure frequency in people with drug‐resistant focal epilepsy. Two studies were at high risk of attrition bias (<a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a>; <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a>); they did not provide reasons for the differences in the number of participants between the intention‐to‐treat (ITT) and per protocol set (PPS). However, the conclusions were unchanged following best‐case (relative risk (RR) 2.23, 95% confidence interval (CI) 1.93 to 2.58) and worst‐case (RR 1.44, 95% CI 1.26 to 1.64) scenario analysis on 50% responder rate. The data from <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a> provided some evidence of a dose‐response relationship, although minimal effective or maximal tolerated doses have not yet been defined. Also, the study by <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a> performed a dose‐response analysis, and found no difference in efficacy at dosage of 100 mg/day and 200 mg/day. Treatment in the included trials ranged from 12 to 18 weeks, so we are unable to draw conclusions about longer‐term efficacy. </p> <p>Five trials included in this review were sponsored by industry (Dainippon or Elan Pharma; <a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>; <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>; <a href="./references#CD001416-bbs2-0003" title="GuerriniR , RosatiA , SegiethJ , PellacaniS , BradshawK , GiorgiL . A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia2013;54(8):1473-80. ">Guerrini 2013</a>; <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>; <a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>). No sources of funding were used to assist in the conduct or preparation of <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a>, but the drug was provided for the trial by two different manufacturers of zonisamide (Eisai Co. Ltd and Shenzhen Zifu Co. Ltd). Two studies did not provide details on funding (<a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a>; <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a>). </p> <p>Results for the outcome withdrawal of allocated treatment indicated that zonisamide was more likely to be associated with withdrawal than placebo, an effect that was likely to be related to a higher incidence of adverse effects with active drug treatment. Ataxia, somnolence, agitation, and anorexia were the common adverse effects that were more likely to occur with zonisamide than placebo. These clinical trials did not provide meaningful information about important safety issues, such as acute idiosyncratic drug reactions, chronic toxicity, or teratogenicity. </p> </section> <section id="CD001416-sec-0073"> <h3 class="title" id="CD001416-sec-0073">Overall completeness and applicability of evidence</h3> <p>While this review offered moderate‐certainty evidence of the efficacy of zonisamide for focal epilepsy as an add‐on treatment, it did not allow comparisons with other antiepileptic drugs (AED). Prospective, actively controlled studies will be necessary to address this question. Similarly, this review provided no information to support the use of zonisamide as either monotherapy, or in people with other epilepsy syndromes. None of the studies included in this review recruited significant numbers of children, and some caution should be exercised in extrapolating the results from adult studies to children with focal epilepsy. </p> </section> <section id="CD001416-sec-0074"> <h3 class="title" id="CD001416-sec-0074">Quality of the evidence</h3> <p>All included studies were defined as double‐blind and six were at low risk of bias due to having used adequate methods of allocation concealment (<a href="./references#CD001416-bbs2-0001" title="BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial. Epilepsia2004;45(Suppl 7):131, Abstract no: 1.343. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyV . Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study. Epilepsia2004;45(Suppl 3):155, Abstract no: p398. BrodieMJ , DuncanR , VespignaniH , SolyomA , BitenskyyV , LucasC . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia2005;46(1):31-41. BrodieMJ , VespignaniH . Efficacy of zonisamide against refractory partial seizures in an evaluable patient population. Epilepsia2005;46(Suppl 6):117-8, Abstract no: p247. ">Brodie 2005</a>; <a href="./references#CD001416-bbs2-0002" title="FaughtE , AyalaR , MontourisGG , LeppikIE . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology2001;57(10):1774-9. ">Faught 2001</a>; <a href="./references#CD001416-bbs2-0004" title="LuY , XiaoZ , YuW , XiaoF , XiaoZ , HuY , et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy. Clinical Drug Investigation2011;31(4):221-9. [DOI: 10.2165/11539750-000000000-00000]">Lu 2011</a>; <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>; <a href="./references#CD001416-bbs2-0003" title="GuerriniR , RosatiA , SegiethJ , PellacaniS , BradshawK , GiorgiL . A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia2013;54(8):1473-80. ">Guerrini 2013</a>; <a href="./references#CD001416-bbs2-0008" title="ZhangL , LiuY , DingC , ShiS , LinW , ChenT , et al. The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial. Chinese Journal of Contemporary Neurology and Neurosurgery2011;11(4):408-12. ">Zhang 2011</a>), while this risk was unclear in two studies (<a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>; <a href="./references#CD001416-bbs2-0007" title="WuX , WuLW , WangYP , HongZ , ZhaoZX , HuangYG , et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures. Chinese Journal of Neurology2010;43(7):459-63. ">Wu 2010</a>). The detailed internal company report of <a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a> indicated that 144 participants were randomised into this study, although the published paper indicated that 139 participants were randomised. The numbers of responders differed slightly because for this review, we only considered the eight weeks immediately before randomisation to constitute the baseline, rather than a varied period of between eight to 12 weeks. In the previous versions of this review, the incidence of different types of adverse events differed, as previous review authors used figures derived from a later application of an updated lexicon and correction of previous duplicate reporting (<a href="./references#CD001416-bbs2-0037" title="ChadwickDW , MarsonAG . Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews2002, Issue 2. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416]">Chadwick 2002</a>; <a href="./references#CD001416-bbs2-0038" title="ChadwickDW , MarsonAG . Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416.pub2]">Chadwick 2005</a>; <a href="./references#CD001416-bbs2-0036" title="CarmichaelK , PulmanJ , LakhanSE , ParikhP , MarsonAG . Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No: CD001416. [DOI: 10.1002/14651858.CD001416.pub3]">Carmichael 2013</a>). </p> <p>We therefore assessed six of the included studies to be at unclear or low risk of bias for all domains, and two studies at high risk of attrition bias. Adopting the GRADE methodology, we assessed the certainty of evidence as moderate for most outcomes (see <a href="./full#CD001416-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD001416-sec-0075"> <h3 class="title" id="CD001416-sec-0075">Potential biases in the review process</h3> <p>There were no potential biases in the review process. More specifically, we did not make decisions that might have introduced bias into the review findings, with regard to the following domains: study eligibility criteria; identification and selection of studies; data collection and study appraisal; and, synthesis and findings (<a href="./references#CD001416-bbs2-0033" title="WhitingP , SavovićJ , HigginsJP , CaldwellDM , ReevesBC , SheaB , DaviesP , KleijnenJ , ChurchillR , ROBIS group. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. Journal of Clinical Epidemiology2016;69:225-34.">Whiting 2016</a>). </p> </section> <section id="CD001416-sec-0076"> <h3 class="title" id="CD001416-sec-0076">Agreements and disagreements with other studies or reviews</h3> <p>We found only one other systematic review evaluating the efficacy and tolerability of add‐on zonisamide for focal epilepsy (<a href="./references#CD001416-bbs2-0023" title="MarsonAG , HuttonJL , LeachJP , CastilloS , SchmidtD , WhiteS , et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Research2001;46(3):259-70.">Marson 2001</a>). This systematic review was conducted by three of the authors who carried out the previous version of this Cochrane Review (AG Marson, JL Hutton, and DW Chadwick), and adopted similar inclusion criteria and methodology. Their review identified and included three studies (total of 499 participants), two of which were published in full (<a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>; <a href="./references#CD001416-bbs2-0034" title="WilderBJ , RamsayRE , GutermanA . Double blind multicenter placebo-controlled study of the efficacy and safety of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal Report of the Dianippon Pharmaceutical Co1986. [CRSREF: 2934611]">Wilder 1986</a>), and one in an abstract (<a href="./references#CD001416-bbs2-0027" title="PadgettCS , AyalaR , MontourisGD . Zonisamide efficacy and dose response. Epilepsia1997;38 Suppl 8:38-74.">Padgett 1997</a>). We included two of these studies in this Cochrane Review (<a href="./references#CD001416-bbs2-0006" title="SchmidtD , JacobR , LoiseauP , DeisenhammerE , KlingerD , DesplandA , et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Research1993;15(1):67-73. ">Schmidt 1993</a>; <a href="./references#CD001416-bbs2-0034" title="WilderBJ , RamsayRE , GutermanA . Double blind multicenter placebo-controlled study of the efficacy and safety of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal Report of the Dianippon Pharmaceutical Co1986. [CRSREF: 2934611]">Wilder 1986</a>). When the results of <a href="./references#CD001416-bbs2-0034" title="WilderBJ , RamsayRE , GutermanA . Double blind multicenter placebo-controlled study of the efficacy and safety of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal Report of the Dianippon Pharmaceutical Co1986. [CRSREF: 2934611]">Wilder 1986</a> were published in <a href="./references#CD001416-bbs2-0005" title="SackellaresJC , RamsayRE , WilderBJ , Browne TRIII , ShellenbergerMK . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia2004;45(6):610-7. WilderBJ , RamsayRE , GutermanA . A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Company1986. ">Sackellares 2004</a>, we included this report. <a href="./references#CD001416-bbs2-0023" title="MarsonAG , HuttonJL , LeachJP , CastilloS , SchmidtD , WhiteS , et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Research2001;46(3):259-70.">Marson 2001</a> found that zonisamide reduced seizure frequency (50% of responders who were taking a median dose of 400 mg/day showed a RR of 2.46, 95% CI 1.61 to 3.76). Participants in the add‐on zonisamide group were also more likely to withdraw than those who received placebo (RR for treatment withdrawal 1.64, 95% CI 1.02 to 2.62). Overall, the results of <a href="./references#CD001416-bbs2-0023" title="MarsonAG , HuttonJL , LeachJP , CastilloS , SchmidtD , WhiteS , et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Research2001;46(3):259-70.">Marson 2001</a> were consistent with our present Cochrane Review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001416-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/urn:x-wiley:14651858:media:CD001416:CD001416-FIG-01" target="_blank"><b></b></a></p> </div><img alt="This diagram refers only to results of the updated searches for the current version of the review" data-id="CD001416-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_t/tCD001416-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>This diagram refers only to results of the updated searches for the current version of the review </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full#CD001416-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001416-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/urn:x-wiley:14651858:media:CD001416:CD001416-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD001416-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_t/tCD001416-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full#CD001416-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001416-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/urn:x-wiley:14651858:media:CD001416:CD001416-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Zonisamide versus placebo, Outcome 1: 50% responder rate ‐ whole treatment period" data-id="CD001416-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_t/tCD001416-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Zonisamide versus placebo, Outcome 1: 50% responder rate ‐ whole treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/references#CD001416-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001416-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/urn:x-wiley:14651858:media:CD001416:CD001416-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Zonisamide versus placebo, Outcome 2: 50% responder rate ‐ best‐case scenario" data-id="CD001416-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_t/tCD001416-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Zonisamide versus placebo, Outcome 2: 50% responder rate ‐ best‐case scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/references#CD001416-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001416-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/urn:x-wiley:14651858:media:CD001416:CD001416-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Zonisamide versus placebo, Outcome 3: 50% responder rate ‐ worst‐case scenario" data-id="CD001416-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_t/tCD001416-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Zonisamide versus placebo, Outcome 3: 50% responder rate ‐ worst‐case scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/references#CD001416-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001416-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/urn:x-wiley:14651858:media:CD001416:CD001416-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Zonisamide versus placebo, Outcome 4: 50% responder rate ‐ dose‐effect for Brodie 2005" data-id="CD001416-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_t/tCD001416-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Zonisamide versus placebo, Outcome 4: 50% responder rate ‐ dose‐effect for Brodie 2005 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/references#CD001416-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001416-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/urn:x-wiley:14651858:media:CD001416:CD001416-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Zonisamide versus placebo, Outcome 5: 50% responder rate ‐ dose effect for Faught 2001" data-id="CD001416-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_t/tCD001416-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Zonisamide versus placebo, Outcome 5: 50% responder rate ‐ dose effect for Faught 2001 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/references#CD001416-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001416-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/urn:x-wiley:14651858:media:CD001416:CD001416-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Zonisamide versus placebo, Outcome 6: Withdrawal rates" data-id="CD001416-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_t/tCD001416-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Zonisamide versus placebo, Outcome 6: Withdrawal rates</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/references#CD001416-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001416-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/urn:x-wiley:14651858:media:CD001416:CD001416-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Zonisamide versus placebo, Outcome 7: Adverse effects" data-id="CD001416-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_t/tCD001416-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Zonisamide versus placebo, Outcome 7: Adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/references#CD001416-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/media/CDSR/CD001416/image_n/nCD001416-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001416-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Zonisamide compared to placebo for focal epilepsy</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Zonisamide compared to placebo for focal epilepsy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with focal epilepsy<br/><b>Setting:</b> hospital outpatients<br/><b>Intervention:</b> add‐on zonisamide<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with zonisamide</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>50% responder rate</b> </p> <p><i>(whole treatment period; any dose</i>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.86<br/>(95% CI 1.60 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1429<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Zonisamide 300 mg to 500 mg/day (RR 1.90, 95% CI 1.63 to 2.22; moderate‐certainty evidence) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>461 per 1000<br/>(396 to 537) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawal rates</b> </p> <p><i>(whole treatment period; any dose)</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.44<br/>(95% CI 1.08 to 1.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1156<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Zonisamide 300 mg to 500 mg/day (RR 1.59, 95% CI 1.18 to 2.13; moderate‐certainty evidence) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000<br/>(119 to 213) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: ataxia</b> </p> <p><i>(whole treatment period; any dose</i>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.85<br/>(99% CI 1.36 to 10.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>734<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Note that for adverse events, we used a 99% CI.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000<br/>(24 to 189) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: dizziness</b> </p> <p><i>(whole treatment period; any dose</i>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/>(99% CI 0.90 to 2.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1429<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000<br/>(68 to 164) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: fatigue</b> </p> <p><i>(whole treatment period; any dose</i>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.41<br/>(99% CI 0.79 to 2.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1045<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000<br/>(43 to 137) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: nausea</b> </p> <p><i>(whole treatment period; any dose</i>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10<br/>(99% CI 0.58 to 2.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>805<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<br/>(38 to 139) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: somnolence</b> </p> <p><i>(whole treatment period; any dose</i>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.52<br/>(99% CI 1.00 to 2.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1636<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000<br/>(72 to 166) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The assumed control risk (ACR) was calculated using median control group risk across the studies that provided data for that outcome.. The corresponding intervention risk in the zonisamide group (and its 95% CI) was based on the assumed risk in the comparison group (ACR) and the relative effect of the intervention (and its 95% CI) and is calculated according to following formula: corresponding intervention risk, per 100 = 100 * ACR * RR. </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty.</b>  We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty.</b>  We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty.</b>  Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for methodological uncertainties in included studies (unclear risk of bias). Some studies were at high risk of attrition bias; they did not provide reasons for differences between the number of patients in ITT and in per protocol set (PPS). However, the conclusions were unchanged following best‐case (RR 2.22, 95% CI 1.92 to 2.57) and worst‐case (RR 1.44, 95% CI 1.26 to 1.64) scenario analysis. <br/><sup>b</sup>Downgraded once for imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Zonisamide compared to placebo for focal epilepsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/full#CD001416-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001416-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Zonisamide versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 50% responder rate ‐ whole treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Any dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.60, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 300 mg to 500 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [1.63, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 50% responder rate ‐ best‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [1.92, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 50% responder rate ‐ worst‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.26, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 50% responder rate ‐ dose‐effect for Brodie 2005 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 300 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 500 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 50% responder rate ‐ dose effect for Faught 2001 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 200 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 400 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Withdrawal rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Any dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.08, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 300 mg to 500 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.18, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Ataxia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.85 [1.36, 10.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.90, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1045</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.79, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.58, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.5 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.00, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.6 Agitation or irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [1.05, 5.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.7 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [1.64, 4.60]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Zonisamide versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001416.pub5/references#CD001416-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001416.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001416-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001416-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001416-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD001416-note-0007">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD001416-note-0005">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD001416-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001416-note-0004">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001416\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001416\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001416\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001416\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001416\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001416.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001416.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001416.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001416.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001416.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728561624"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001416.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728561627"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001416.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec770f8e0f431',t:'MTc0MDcyODU2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 